News
FDA hands another rejection to Replimune's melanoma therapy
Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
Market Access
For life sciences, it’s not only about when to bring on a GC...
For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
News
Diagnostics lag is holding back new therapies, says study
Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
Market Access
A step forward, but not the finish line: What NICE’s QALY up...
Healthcare in the UK is at an inflection point.
News
AbbVie tries a new approach in 340B programme battle
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
